Abiomed to Host Virtual Clinical Data and Innovation Day
May 20 2020 - 7:00AM
Business Wire
Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough
heart support technologies, today announced that it will host a
Virtual Investor Day covering Clinical Data & Innovation on May
27, 2020 from 8:30 a.m. – 12:00 p.m. EDT. The event will include
presentations from members of Abiomed’s senior management team and
5 Physicians Experts providing an overview and update on the
company’s clinical data and latest innovations that have been
recently launched or are expected to be launched commercially over
the next few years.
A live webcast of the event will be available May 27 via the
link https://innovationday.abiomed.com. The webcast will also be
available on the investor section of the company's website at
www.abiomed.com. A replay of the webcast will be available on the
investor section of the company's website after the event.
ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc. is a leading
provider of medical devices that provide circulatory support. Our
products are designed to enable the heart to rest by improving
blood flow and/or performing the pumping of the heart. For
additional information, please visit: www.abiomed.com.
FORWARD-LOOKING STATEMENTS
This release contains forward-looking statements, including,
without limitation, statements regarding development of Abiomed's
existing and new products, the company's progress toward commercial
growth, and future opportunities and expected regulatory approvals.
All statements, other than statements of historical facts, may be
forward-looking statements. These forward-looking statements may be
accompanied by such words as “anticipate,” “believe,” “estimate,”
“expect,” “forecast,” “intend,” “may,” “plan,” “potential,”
“project,” “target,” “should,” “likely,” “will” and other words and
terms of similar meaning. The company's actual results may differ
materially from those anticipated in these forward-looking
statements based upon a number of factors, including, without
limitation: the scope, scale and duration of the impact of the
COVID-19 pandemic, uncertainties associated with development,
testing and related regulatory approvals, including the potential
for future losses, complex manufacturing, high quality
requirements, dependence on limited sources of supply, competition,
technological change, government regulation, litigation matters,
future capital needs and uncertainty of additional financing, and
other risks and challenges detailed in the Company's filings with
the Securities and Exchange Commission, including the most recently
filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q.
Readers are cautioned not to place undue reliance on any
forward-looking statements, which speak only as of the date of this
release. The Company undertakes no obligation to publicly release
the results of any revisions to these forward-looking statements
that may be made to reflect events or circumstances that occur
after the date of this release or to reflect the occurrence of
unanticipated events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200520005068/en/
Todd Trapp Vice President and Chief Financial Officer
978-646-1680 ttrapp@abiomed.com
Tom Langford Director, Communications and Public Relations
978-882-8408 tlangford@abiomed.com
ABIOMED (NASDAQ:ABMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
ABIOMED (NASDAQ:ABMD)
Historical Stock Chart
From Apr 2023 to Apr 2024